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Abstract: Tuberculosis (TB) is a bacterial disease responsible for millions of infections and preventable
deaths each year. Its treatment is complicated by patients’ noncompliance due to dosing frequency,
lengthy treatment, and adverse side effects associated with current chemotherapy. However,
no modifications to the half-a-century old standard chemotherapy have been made based on a
nanoformulation strategy to improve pharmacokinetic efficacy. In this study, we have designed a
new nanodelivery formulation, using graphene oxide as the nanocarrier, loaded with the anti-TB
antibiotic, ethambutol. The designed formulation was characterized using a number of molecular
analytical techniques. It was found that sustained release of the drug resulted in better bioavailability.
In addition, the designed formulation demonstrated high biocompatibility with mouse fibroblast
cells. The anti-TB activity of the nanodelivery formulation was determined using whole-cell resazurin
microtiter plate assay, modified-spot culture growth inhibition assay, and biofilm inhibition assay.
The nanodelivery formulation showed good anti-mycobacterial activity. The anti-mycobacterial
activity of Ethambutol was unaffected by the drug loading and release process. The results of this
study demonstrated the potential of this new nanodelivery formulation strategy to be considered for
modifying existing chemotherapy to yield more efficacious antibiotic treatment against TB.
Keywords: graphene oxide; nanocarrier; ethambutol; tuberculosis; nanodelivery formulation
1. Introduction
Despite leaps in technological advancement, tuberculosis (TB) is still killing 1.5 million people
every year. TB treatment is complicated by patient noncompliance due to the side effects of the currently
available drugs, frequent dosing, and the lengthy treatment duration [1–3]. Nanotechnology is a rapidly
advancing scientific field with a wide range of applications in electronics, healthcare, and engineering,
that can potentially be used for anti-TB treatment [4–6]. In healthcare, nanomedicine for the delivery of
therapeutics is receiving attention because of the fascinating properties of nanoparticles that are absent
Molecules 2017, 22, 1560; doi:10.3390/molecules22101560 www.mdpi.com/journal/molecules
Molecules 2017, 22, 1560 2 of 12
from their bare counterparts [7]. Graphene and its derivative materials are being widely explored
and applied in various fields of science and technology, such as electronics, material science, sensing
technology, engineering photonics, and biomedical sciences [8–11].
The nanodrug delivery platform is a subject of rapid growth because of its significant role in the
improvement of therapeutic values of different drugs and bioactive molecules by modulating their release
profiles, bioavailability, and solubility, and protecting the drug from degradation [5,12,13]. Increased
efforts are now being invested into engineering multifunctional, biocompatible nanomaterials for the
delivery of drugs at the site of infection thereby resulting in more effective therapy [14–17]. Different
nanomaterials such as liposomes, polymers, micelles, carbon nanotubes, quantum dots, dendrimers,
metallic nanoparticles, and graphene oxide (GO) have been applied for the delivery of different drugs
and biomolecules [18–27].
Among all of these nanomaterials, GO has garnered the most attention due to its favourable
electrical, chemical, thermal, optical, mechanical, and biological properties. GO is cheap, has good
dispersibility in water and physiological solutions, good tensile strength, the sustained-release property,
large surface area, low toxicity, and excellent biocompatibility making it an ideal candidate for drug
delivery applications [12,28–30]. The 2D aromatic surface with oxygenated functional groups of GO
makes it an ideal substrate for drug loading via different electrostatic interactions between the drugs
and the host, GO [12,30].
Ethambutol [(+)-2,2-(ethylenediimino)di-1-butanol)] (ETB) has been used for the treatment of
tuberculosis since 1966 [31]. The initial dose of ethambutol is 15 mg/kg of body weight per day. It is
a first line anti-TB drug with side effects such as loss of appetite, headache, nausea, stomach upset,
dizziness, vomiting, abdominal pain, worsening gout, or joint pain [31,32]. In this study we have
designed an anti-tuberculosis nanodelivery formulation using GO as the nanocarrier and ETB as the
guest drug. The designed formulation was thoroughly characterized using XRD, FTIR, TEM, HPLC
and Raman spectroscopy. The designed formulation was also evaluated for in vitro sustained release,
biocompatibility and therapeutic efficacy.
2. Results
2.1. Physico-Chemical Characterisation of ETB-GO
2.1.1. Powder X-ray Diffraction (XRD)
Figure 1a shows the XRD patterns of graphite (Gr), the nanocarrier graphene oxide (GO), the
free drug ethambutol and the nanodelivery formulation composed of ethambutol loaded on graphene
oxide (ETB-GO). The starting material Gr showed a characteristic sharp peak due to the diffraction
pattern of the highly graphitic plane (002) at 2θ = 26.27◦, having well-organized layers with basal
spacing of 3.4 Å [5,12]. The nanocarrier GO was prepared from Gr, and the successful formation
of GO is confirmed by the disappearance of the graphite peak at 2θ = 26.27◦ and the appearance of
a new peak of GO at about 2θ = 10.0◦, attributed to the diffraction of the (001) planes of GO with
increased basal spacing of 8.8 Å [33]. The increase in the basal spacing of GO can be attributed to
the increase in the interlayer distance, exfoliation of Gr layers, and formation of oxygenated layers of
GO [15]. Three crystalline intense peaks were observed for the pure drug ETB at 2θ of 7.86◦, 15.48◦
and 23.25◦, corresponding to the crystalline characteristics of the organic molecule [12]. In contrast,
the nanodelivery formulation ETB-GO showed a small hub of ETB peaks at 15.48◦, which shows
amorphous characteristics compared with the XRD pattern of the pure drug. The absence of the XRD
pattern of the organic drug molecules after loading is a normal phenomenon and has been reported
previously [5,12,34]. However, the GO peak is present in the nanocomposite formulation, ETB-GO.
The successful loading of ETB was further confirmed by other complementary techniques and will be
discussed later.
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Figure 1. (a) XRD patterns of graphite (Gr), Graphene oxide (GO), ETBambutol (ETB), and the 
nanodelivery formulation ETB-GO. (b) FTIR spectra of the nanocarrier GO, free drug ETB, and ETB-
GO; (c) Raman spectra of Gr, GO, and ETB-GO. (d) Transmission electron micrographs of Gr, GO, 
and ETB-GO, and the particle size distribution of ETB-GO. (e) (A) In vitro release of ETB from the 
nanodelivery formulation ETB-GO in PBS solution of pH 7.4 and PBS solution of pH 4.8. In vitro 
release profile of free drug ETB in PBS solution of pH 7.4 and pH 4.8 (e) (B). 
Figure 1. (a) XRD patterns of graphite (Gr), Graphene oxide (GO), ETBambutol (ETB), and the
nanodelivery formulation ETB-GO. (b) FTIR spectra of the nanocarrier GO, free drug ETB, and
ETB-GO; (c) Raman spectra of Gr, GO, and ETB-GO. (d) Transmission electron micrographs of Gr,
GO, and ETB-GO, and the particle size distribution of ETB-GO. (e) (A) In vitro release of ETB from
the nanodelivery formulation ETB-GO in PBS solution of pH 7.4 and PBS solution of pH 4.8. In vitro
release profile of free drug ETB in PBS solution of pH 7.4 and pH 4.8 (e) (B).
Molecules 2017, 22, 1560 4 of 12
2.1.2. Fourier Transformed Infrared Analysis
Fourier transformed infrared (FTIR) analysis is the major analytical technique used for the
detection of functional groups of molecules. Figure 1b shows the FTIR spectra of ETB, GO, and ETB-GO.
The FTIR spectrum of GO shows the characteristic bands of oxygenated functional groups such as a
hydroxyl stretching absorption bands at 3429 cm−1, a carbonyl (C=O) stretching band at 1629 cm−1,
and alkoxyl and epoxide stretching bands at about 1064 cm−1 [5,12,33,35]. The free drug showed
characteristic functional group bands of N–H stretching at about 3739 cm−1, O–H stretching vibration
at about 3429 cm−1, C–H stretching vibration at 2975 cm−1 and 2809 cm−1, and a C–N stretching
vibration band at about 1060 cm−1 [36,37]. The FTIR spectrum of the nanodelivery formulation
ETB-GO showed the FTIR vibrational bands of both the nanocarrier and the pure ETB at similar
positions. The presence of functional group bands belonging to ETB and GO in the spectrum of the
nanodelivery formulation is strong evidence for the successful formation of the ETB-GO.
2.1.3. Raman Spectroscopy
Raman spectroscopy is a powerful tool to analyze the disorder, defects, and structural changes
in carbon-based material after chemical modifications [38]. Figure 1c shows the Raman spectra of
Gr, GO and ETB-GO. The Raman spectrum of Gr shows two main graphitic characteristic peaks:
the D–band corresponding to the disorder-induced mode and the G-band ascribed to the graphitic-like
mode appeared at 1349 cm−1 and 1557 cm−1, respectively [38]. The D-band, corresponding to the
nanocrystalline quality of the carbon structures, is due to disorder or defects in the material and its
high intensity is due to the presence of more sp2 domains. The G-band is related to the high degree
of order of the crystalline graphitic structure [39–41]. The successful formation of the nanocarrier
GO was confirmed by the shift and the intensity change of the D and G bands at 1249 cm−1 and
the G band at 1594 cm−1, respectively. The nanodelivery formulation also showed the shift in D
and G bands to 1357 cm−1 and 1581 cm−1 respectively. The ID/IG ratio for GO and ETB-GO was
found to be 1.0 compared to 0.833 for Gr. The increase in value of the ID/IG ratio is in agreement
with previous studies [5,39]. The results from the Raman studies strongly complement the XRD and
FTIR results, which support the successful formation of the nanocarrier GO and the nanocomposite
formulation ETB-GO.
2.1.4. Transmission Electron Microscopy (TEM) Analysis
The structural features and morphology of the starting material (graphite), the nanocarrier, and the
nanodelivery formulation were determined using transmission electron microscopy. Figure 1d shows
the TEM micrographs of the three materials together with the particle size distribution of ETB-GO. It is
very clear from TEM micrograph of Gr that it contains a bunch of graphene sheets stacked together.
However, we can observe a single sheet of GO in the TEM micrograph, which is strong evidence for
the successful oxidative exfoliation of Gr to GO. The TEM micrograph of the nanodelivery formulation
ETB-GO shows the particulate formation after the loading process. The particle size of ETB-GO was
determined using Image analysis software and SPSS software. About 111 particles (N) were randomly
selected and their mean size was determined to be 59 nm with a standard deviation of 11 nm.
2.1.5. In Vitro Release Study
Ultraviolet-visible (UV/Vis) spectroscopy was used for the in vitro release of ETB from ETB-GO
and for the release profile of the free drug ETB in human body-simulated phosphate buffered saline
(PBS) solutions of pH 7.4 and pH 4.8. Figure 1e (A) shows the in vitro release behavior of ETB from
ETB-GO in PBS solutions of pH 7.4 and pH 4.8. The release was found to be similar at both pH
levels tested. The sustained release took about 1500 min (25 h) for the solution to become saturated
and a plateau to be observed, which suggests that the release was completed by that time period.
The mechanism of release of the drug from the GO nanocarrier has been reported to involve the
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ion exchange process of GO with the anions present in the buffer solutions [5,41–43]. The sustained
release of ETB up to 1500 min also suggests the successful loading of the ETB on the GO with
a strong interaction between them. The free drug ETB took about 10 min for complete release
as shown in Figure 1e (B), which is far faster in comparison with the release from the designed
formulation. The sustained release would enhance the bioavailability of the drug which would
translate to improving the therapeutic efficacy and therefore may also allow for the reduction in dosing
frequency of the drug.
2.2. Biological Evaluation of ETB-GO
2.2.1. Antimycobacterial Activity of ETB-GO on Planktonic Cells
Figure 2a shows the growth inhibition properties of ETB, GO, and ETB-GO on M. smegmatis.
The MIC of the free drug ETB and of the nanodelivery formulation was found to be 0.39 µg/mL
and 1.5 µg/mL, respectively, as shown in Table 1. However, the percentage loading of ETB in
the nanodelivery formulation was found to be 47.96%, determined by using HPLC. Based on
this, the amount of ETB present in 1.5 µg of ETB-GO would be 0.72 µg (effective MIC). A similar
anti-mycobacterial effect is also observed in the modified SPOTi assay (Table 1). This indicates drug
loading and release processes do not considerably affect the activity of the drug ETB.
Table 1. The minimum inhibitory concentration of the compounds tested based on the liquid culture
REMA assay with M. smegmatis.
Compound
REMA Modified SPOTi
Observed MIC (µg/mL) Effective MIC (µg/mL) Observed MIC (µg/mL) Effective MIC (µg/mL)
ETB 0.39 0.39 0.39 0.39
ETBGO 1.5 0.72 1.5 0.72
2.2.2. Biofilm Inhibition by ETB-GO
ETB-GO was found to inhibit M. smegmatis biofilm formation at 3.12 µg/mL (effective
concentration 1.496 µg/mL) which is higher than the MIC of the planktonic bacterial cells (Figure 2b
and c). This is not unusual as biofilms are tolerant of external pressures such as antibiotics and require
higher exposures for longer periods of time for their elimination [44]. ETB biofilm inhibitory properties
have been reported earlier [45]. Overall, ETB was better in inhibiting the M. smegmatis biofilm than the
nanoformulation. The reduced activity may indicate that the slow release of the drug is not effective
against a biofilm colony.
2.2.3. Cytotoxicity Studies
The biocompatibility of the material considered for health care applications is the key aspect
of drug delivery research. These studies were performed on 3T3 mouse fibroblast cells wherein the
cells were incubated for maximum incubation period of 72 h with ETB, GO, and ETB-GO using a
concentration gradient between 0.78 µg/mL and 50 µg/mL. The cell viability was determined using
MTT assay. After 72 h of incubation, all of the samples of ETB, GO, and ETB-GO were found to be highly
biocompatible with more than 85% cell viability as shown in Figure 2d. The nanodelivery formulation
ETB-GO was found to be more biocompatible (cell viability more than 95%) compared to the free drug
ETB (cell viability about 85%) at the highest concentration 50 µg/mL. This suggests that the designed
nanodelivery formulation ETB-GO and its starting material, GO, are highly biocompatible and are
safe for health care applications. The cellular uptake mechanism of the GO-based nanoformulation
is reported to be via endocytosis; uptake begins immediately and smaller nanoparticles with higher
concentration are taken up 1000 times higher than large GO flakes [46,47]. The graphene-based
nanoformulation is removed by the phagocytosis process [48].
Molecules 2017, 22, 1560 6 of 12
Molecules 2017, 22, 1560  6 of 12 
 
 
Figure 2. (a) REMA and SPOTi results based on ethambutol (ETB) and the multifunctional 
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GO. The MIC of ETB-GO was found to be 1.5 μg/mL, however, when treating biofilm, the MIC was 
found 1 fold higher (3.12 μg/mL). (c) Quantification of concentration-dependent biofilm of ETB and 
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Figure 2. (a) REMA and SPOTi results based on ethambutol (ETB) and the multifunctional
nanoformulation ETB-GO tested on M. smegmatis. (b) M. smegmatis biofilm treated with ETB and
ETB-GO. The MIC of ETB-GO was found to be 1.5 µg/mL, however, when treating biofilm, the MIC
was found 1 fold higher (3.12 µg/mL). (c) Quantification of concentration-dependent biofilm of ETB
and ETB-GO by crystal violet. (d) Cell viability of 3T3 cells after 72 h incubation with ETB, GO,
and ETB-GO.
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3. Discussion
In this study we have designed an anti-TB nanodelivery formulation using graphene oxide
as the nanocarrier and an anti-TB drug (ethambutol) as the guest drug. The successful formation
of a nanodelivery formulation was confirmed by various detailed instrumental characterizations.
The designed ETB-GO was found to release the drug in sustained manner over an extended period of
25 h in human body-simulated PBS solutions of pH 7.4 and pH 4.8. Sustained-release formulations
provide controlled dispersal of the drug, thereby maximizing the time during which the peak
concentration is maintained in a patient while minimizing the cytotoxic effects [49]. Augmentin
XR (amoxicillin/clavulanate with hypromellose) is a slow-release antibiotic formulation currently
on the market which has improved treatment outcomes and reduced treatment costs [50]. Zhu et al.
reported lower than expected maximum serum concentrations (Cmax) in adults [51]. In pediatric
patients this value was lower and delayed absorption of the drug was also reported. Many Cmax were
found to be sub-minimal inhibitory concentrations, allowing for the development of a resistant-strain
selective environment. Nanoformulations and alternate drug delivery systems or administration routes
may impact the pharmacokinetics of the drug to the benefit of the patient by improving absorption
and retention periods in systemic circulation.
Graphene oxide has achieved much success as a drug delivery system for anti-cancer drugs since
the first report by Liu et al. [52]. The ethambutol-containing nanodelivery formulation was found to
be biocompatible with 95% of the 3T3 cells surviving an exposure of 50 µg/mL of the nanoformulation
over a period of 72 h. The therapeutic efficacy determined using REMA, modified SPOTi, and biofilm
inhibition against Mycobacterial smegmatis revealed that ETB retains its growth inhibitory property.
Sustained release of the potent first-line anti-TB drug would be beneficial for improving the drug
bioavailability and therapeutic efficacy with reduced dosing frequency. This modification would have
a significant impact on the design of drug treatment regimens with implications of improving patient
compliance. Therefore we believe these results provide a firm basis for in vivo studies.
4. Materials and Methods
4.1. Chemicals
Ethambutol dihydroxychloride (99% purity), potassium permanganate (KMnO4), hydrogen
peroxide (H2O2), graphite flakes with 109 meshes, sulphuric acid (H2SO4, 98%), phosphate-buffered
saline, and phosphoric acid (H3PO4) were purchased from Sigma Aldrich (St Louis, MO, USA) and
used without further purification. Diethyl ether, sodium hydroxide, and hydrochloric acid (HCl, 37%)
were purchased from Friedemann Schmidt (Parkwood, WA, USA). Normal fibroblast (3T3) cell lines
were purchased from the American Tissue Culture Collection (Manassas, VA, USA) and deionized
water was used in all experiments.
4.2. Instrumentation
For X-ray diffraction (XRD) studies, a Shimadzu XRD-6000 Diffractometer (Shimadzu Corporation,
Tokyo, Japan), was utilized with CuKα radiation at 30 kV and 30 mA. For the functional group analysis,
a Perkin-Elmer (Waltham, MA, USA) 100 series spectrophotometer Fourier Transform infrared (FTIR)
was used, and spectra were recorded by the direct sample method. For the optical and release studies,
a Lambda 35 ultraviolet-visible spectrophotometer (Perkin Elmer) was used. A Raman spectrometer,
Witec Model: Alpha 300R was used for the RAMAN analysis of the samples with 532 nm excitation. For
drug quantification, Sykam high performance liquid chromatography (HPLC) system (SYKAM GmbH,
Eresing, Germany) was used with the auto injector Sykam 5300, a Sykam S3250 UV/Vis detector, and
the Sykam quaternary pump system 5300 made in Germany, with a Zorbax Rx-Sil column of 4.6 × 150
mm, and with 5 µm particle size (Agilent Technologies, Santa Clara, CA, USA).
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4.3. Synthesis of Graphene Oxide
The graphene oxide was synthesized by oxidative exfoliation using improved Hummer’s method.
In brief, 3 g of graphite powder and 18 g of KMnO4 were added to 400 mL (360 mL concentrated
H2SO4 + 40 mL concentrated H3PO4) and the solution was then stirred continuously at a constant heat
of 50 ◦C for 12 h. After 12 h, the sample was allowed to cool and then poured on 400 g of ice cubes
containing 3 mL of H2O2. The final product was subjected to work-up by washing with deionized
water, concentrated HCl, and ethanol (200 mL of each, respectively), and then coagulated with 200 mL
diethyl ether. The product was dried in an oven at 40 ◦C [33].
4.4. Preparation of Anti-TB Nanodelivery Formulation (ETB-GO)
The anti-TB nanodelivery formulation was prepared by loading the anti-TB drug ETB onto
graphene oxide (ETB-GO), by adding 0.2 g of GO into 2% solution of ETB and maintaining the pH of
the mixture at pH = 5. The sample was stirred overnight at room temperature and the resulting slurry
was washed thoroughly with water, centrifuged, and dried at 40 ◦C.
4.5. In Vitro Sustained Release
Release studies were conducted in human body-simulated phosphate buffer saline (PBS) solution
of 0.1 M with pH of 7.4 (blood pH) and 4.8 (intracellular lysosomal pH). About 4 mg of the nanodelivery
formulation of ETB-GO was added into 3.5 mL of pH 7.4 and 4.8 solutions separately and the absorption
was taken at 190 nm in a UV/Vis spectrophotometer for the release profile of ETB.
4.6. Drug Loading Quantification by HPLC Analysis
The loading of ETB was quantified using HPLC analysis by utilizing the previously reported
method with a slight modification [1]. In brief, the mobile phase comprised solvent A (acetonitrile)
and solvent B (15 mmol/L potassium dihydrogen phosphate buffer solution), with pH adjusted to
4.0 ± 0.1, used in a ratio of 89:11 with a flow rate of 1 mL/min at 25 ◦C. A UV detector was used with
the selected wavelength of 192 nm. Different concentrations of ETB standard solution were used for a
calibration curve determination and R2 was found to be 0.9973. The retention time for ETB elution was
found to be 2.3 min and the % loading was determined to be 47.96%.
4.7. In Vitro Cytotoxicity Study
MTT Assay for In Vitro Cytotoxicity Studies
For the evaluation of the cytotoxicity profiles, MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay was used as reported previously [1,53,54]. In brief, the eukaryotic
cells (3T3) were seeded into a 96-well plate with the density of 1.0 × 105 cells per well in 100 µL
of cell culture medium, and allowed to attach for 24 h before addition of the samples. After 24 h,
all the samples ETB, GO, and ETB-GO were individually added to the cells at various concentrations
(0.78 to 50 µg/mL), and incubated for 72 h at 37 ◦C in a humidified chamber (5% CO2 atmosphere).
The untreated 3T3 fibroblast cells (cells only, free from any drug or nanoformulation) were considered
as an experimental control. Samples were treated in triplicate for each concentration. Following
the 72 h incubation period, 20 µL of MTT solution (with a concentration of 5 mg/mL) was added
to each well and incubated at 37 ◦C for 4 h. Four hours after MTT addition, dimethyl sulfoxide
(100 µL/well) was added to each well to dissolve the dark blue formazan crystals formed due to
the reduction of tetrazolium by living cells. The concentration of living cells was determined by
measuring the concentration of blue formazan at 570 nm and 630 nm using a microplate enzyme-linked
immunosorbent assay reader (ELx800, BioTek Instruments, Winooski, VT, USA) [53,54]. Cell viability
data were stated as a percentage by comparing with the untreated cells under identical experimental
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conditions. All experiments were carried out in triplicate, and the results are presented as the
mean ± standard deviation.
4.8. Antimycobacterial Assays
4.8.1. Resazurin Microtiter Plate Assay (REMA)
The minimum inhibitory concentration (MIC) of the drug and its nanoformulation were
established by Resazurin Microtiter Plate Assay (REMA). In brief, 2 µL of the drug/nanoformulation
stock of concentration 5 mg/mL was added to 198 µL of media in a microtiter plate and serially
diluted along the columns of the plate. M. smegmatis cells were grown until early-logarithmic phase
(OD600 ~1.00), then diluted (10−3 dilution), and 100 µL of the cell suspension was added to each well.
Solvent (DMSO), carrier (GO), drug-free, and cell-free controls were set up. The plates were incubated
for 24 h at 37 ◦C. After incubation, 30 µL of resazurin dye mixture (1:1 (v/v) of 0.01% (w/v) resazurin
and 20% (v/v) Tween-80%) was added to each well and incubated for a further 6–9 h. A change in
colour of the solution from blue to pink indicates oxidation brought about by active growth of bacteria.
The MIC was determined by the lowest concentration of the compound wherein no colour change is
observed. The experiment was performed in triplicate.
4.8.2. Modified SPOTi Assay
This assay is modified based on the SPOTi experimental method [55–58] to evaluate formulated
compounds more appropriately. The microtiter plate with the drug/nanoformulation and the
M. smegmatis cells were prepared as for the REMA. Solvent (DMSO), carrier (GO), drug-free,
and cell-free controls were set up. The tubes were incubated for 24 h at 37 ◦C shaking at 150 rpm
to keep the nanoformulations uniformly dispersed. After completion of incubation, 2 µL of the cell
suspension was spotted onto microtiter plate with each well containing 200 µL of M7H10 media
(BD Biosciences, Wokingham Berkshire, England) supplemented with 0.02% (v/v) glycerol and 10%
Oleic acid-Albumin-Dextrose-Catalase (OADC, BD Biosciences, UK). The plate was incubated at 37 ◦C
for 48 h or until visible spots of bacterial growth appeared in the drug-free controls. The MIC was
determined as the lowest concentration of the drug/nanoformulation at which no growth of bacteria
was observed. The experiment was performed in triplicate.
4.8.3. Biofilm Inhibition
Biofilm growth and inhibition assay was set up in 96-well plates (Corning, polystyrene,
non-treated). 10 µL of late-logarithmic phase (OD600 ~4) M. smegmatis cells were added to each
well and the final volume made up to 200 µL with Sauton’s media (0.5 g KH2PO4, 0.5 g MgSO4, 4.0 g
L-asparagine, 0.05 g Ferric ammonium citrate, 2.0 g citric acid, and 60 mL glycerol dissolved in 900 mL
dH2O and pH adjusted to 7) containing the drug and its formulation in a range of concentrations
between 25 µg/mL and 0.19 µg/mL. Solvent (DMSO), carrier (GO), drug-free, and cell-free controls
were set up. The biofilms were allowed to grow for 5 days at 37 ◦C under static conditions. At the
end of the incubation period, the media containing planktonic cells was aspirated and the biofilm was
dried in an oven at 50 ◦C for 10 min. A quantity of 200 µL of crystal violet solution (0.1%) was added
to each well and left to incubate for 30 min at room temperature. Finally, 30% acetic acid was added to
solubilize the biofilm, followed by 30 min of incubation at room temperature. The contents of each
well was transferred to a fresh 96-well plate and the absorbance at 600 nm recorded using a Biotek
(Synergy) plate reader. The experiment was performed in triplicate.
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